Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Authorities Have Delayed Approving an Important Drug

Food and Drug Administration (FDA) has delayed the approval of Brilinta, a drug for blood flow produced by AstraZeneca, which will be a major competitor of Plavix, made by Sanofi-Aventis and Bristol-Myers Squibb, the closest second in the world based on sales.

AstraZeneca said it had received a letter from the authority, which requires further analysis of clinical test data, but no additional studies.

Most analysts anticipate that FDA will approve Brilinta until December 20, especially because the deadline has been postponed on 16 September.

Shares of the British group, AstraZeneca, which reached the last meeting the highest level since late October, fell 5.5% to £2.98 per unit.

The company relies heavily on revenue that will be brought Brilinta, already approved in Europe to offset the expiration of patents for some of the best selling drugs, and NEXIUM (for heart disease) and Seroquel (for schizophrenia).

Delaying approval in the U.S. will reduce confidence in the potential drug in the U.S., where it is anticipated that sales will contribute about 10% to group results by 2015.

Analysts have forecast that annual sales could reach into the future Brilinta 2.7 billion dollars.